Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1–resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK, May ...
MiNK Therapeutics, Inc. announced its first-quarter 2025 financial results and highlighted significant progress in its development of allogeneic invariant natural killer T (iNKT) cell therapies. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results